Literature DB >> 33085594

Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display.

Eunike C McGowan1,2,3, Robert L Flower1,2, Martina L Jones2,3, David O Irving1,4, Ross T Barnard2,5, Catherine A Hyland1,2, Stephen M Mahler2,3, Xuan T Bui1,2,3.   

Abstract

BACKGROUND: RhD-immunoglobulin (RhIg) prevents anti-D alloimmunisation in D-negative pregnant women when the fetus is D-positive, reducing the incidence of haemolytic disease of the fetus and newborn. Manufacturing RhIg is reliant on the limited supply of plasma donations with anti-D antibodies. Monoclonal antibody (mAb) development platforms such as phage display, require blood samples to be collected from anti-D donors, which may be a complicated process. The blood filter chamber (BFC) discarded after an anti-D donor's donation might provide a source of Ig-encoding RNA. This study aims to evaluate whether used BFCs are a suitable source of Ig-encoding RNA for phage display.
MATERIAL AND METHODS: Haemonetics PCS2 BFCs were obtained from 10 anti-D donors for total RNA extraction, cDNA synthesis and amplification of VH and VL IgG sequences for assembly of single-chain variable fragments (scFvs). A scFv-phage display library was constructed and 3 rounds of biopanning were performed using D-positive and D-negative red blood cells (RBCs). Positive phage clones were isolated, Sanger sequenced and, where possible, reformatted into full-length human IgGs to define specificity. The BFC aggregates from 2 anti-D donors underwent a Wright-Giemsa stain and hematological cell count.
RESULTS: Of 10 BFCs, a sufficient yield of total RNA for library construction was obtained from BFCs containing cellular aggregates (n=5). Aggregate analysis showed lymphocytes were the cellular source of Ig-encoding RNA. From the 5 samples with aggregates, scFvs were assembled from amplified IgG variable regions. The library constructed from 1 of these samples resulted in the isolation of clones binding to D-positive RBCs with IGHV3 gene usage. Of the 4 reformatted IgG, 3 were anti-D and 1 had undefined specificity. DISCUSSION: BFC aggregates are a new and convenient source of Ig-encoding RNA which can be used to construct Ig gene libraries for mAb isolation and discovery via antibody phage display.

Entities:  

Year:  2020        PMID: 33085594      PMCID: PMC7850920          DOI: 10.2450/2020.0093-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  25 in total

Review 1.  Research and clinical applications of antibody phage display in transfusion medicine.

Authors:  D L Siegel
Journal:  Transfus Med Rev       Date:  2001-01

2.  The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donor.

Authors:  S E Dohmen; O J H M Verhagen; S M de Groot; L M Stott; R C Aalberse; S J Urbaniak; C E van der Schoot
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Collection of white blood cell-reduced plasma by apheresis.

Authors:  Hans Vrielink; Pieter F van der Meer
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157

Review 4.  Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?

Authors:  Davor Brinc; Gregory A Denomme; Alan H Lazarus
Journal:  Curr Opin Hematol       Date:  2009-11       Impact factor: 3.284

5.  The restricted use of IGHV3 superspecies genes in anti-Rh is not limited to hyperimmunized anti-D donors.

Authors:  Serge E Dohmen; Onno J H M Verhagen; Jessica Muit; Peter C Ligthart; C Ellen van der Schoot
Journal:  Transfusion       Date:  2006-12       Impact factor: 3.157

6.  Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.

Authors:  Tadeusz Robak; Jerzy Windyga; Jacek Trelinski; Mario von Depka Prondzinski; Aristoteles Giagounidis; Chantal Doyen; Ann Janssens; María Teresa Alvarez-Román; Isidro Jarque; Javier Loscertales; Gloria Pérez Rus; Andrzej Hellmann; Wieslaw Wiktor Jêdrzejczak; Kazimierz Kuliczkowski; Lana M Golubovic; Dusica Celeketic; Andrei Cucuianu; Emanuil Gheorghita; Mihaela Lazaroiu; Ofer Shpilberg; Dina Attias; Elena Karyagina; Kalinina Svetlana; Kateryna Vilchevska; Nichola Cooper; Kate Talks; Mukhyaprana Prabhu; Prasad Sripada; T P R Bharadwaj; Henrik Næsted; Niels J Ø Skartved; Torben P Frandsen; Mimi F Flensburg; Peter S Andersen; Jørgen Petersen
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

7.  Sequence and specificity analysis of recombinant human Fab anti-Rh D isolated by phage display.

Authors:  S Miescher; M Vogel; C Biaggi; V Ramseyer; H Hustinx; N Eicher; M A Imboden; M O Spycher; H Amstutz; B M Stadler
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

8.  Restricted processing of CD16a/Fc γ receptor IIIa N-glycans from primary human NK cells impacts structure and function.

Authors:  Kashyap R Patel; Jacob T Roberts; Ganesh P Subedi; Adam W Barb
Journal:  J Biol Chem       Date:  2018-01-12       Impact factor: 5.157

9.  Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.

Authors:  B M Kumpel; M J Goodrick; D H Pamphilon; I D Fraser; G D Poole; C Morse; G R Standen; G E Chapman; D P Thomas; D J Anstee
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Targeting membrane proteins for antibody discovery using phage display.

Authors:  Martina L Jones; Mohamed A Alfaleh; Sumukh Kumble; Shuo Zhang; Geoffrey W Osborne; Michael Yeh; Neetika Arora; Jeff Jia Cheng Hou; Christopher B Howard; David Y Chin; Stephen M Mahler
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

View more
  1 in total

1.  Phage display reloaded: on the development of reliable monoclonal antibodies for potential Rh immune globulin production.

Authors:  Gregory A Denomme
Journal:  Blood Transfus       Date:  2021-01       Impact factor: 3.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.